Loading viewer...
other
Format: PDF other
Plainview LLC short-seller report from October 2018 arguing that Nektar Therapeutics' NKTR-214 immunotherapy candidate lacks efficacy and misses clinical thresholds. The report claims the drug's mechanism does not achieve stated objectives and compares results unfavorably to competing candidates like epacadostat.
conference
28 Pages
other
38 Pages
Bespoke Investment Group
USPS Retail Post Office Operations 2023
otherother
44 Pages
United States Postal Service
Catalyst Pharmaceuticals 2021 SASB Sustainability Index
otherother
15 Pages
Catalyst Pharmaceuticals